Bronchogen
/ Khavinson-tradition tetrapeptide (Ala-Glu-Asp-Leu); proposed bronchial epithelium bioregulatorALIAS · AEDL · Ala-Glu-Asp-Leu · Bronchial peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. The published evidence base is a small Russian-origin literature from the Khavinson group at the Saint-Petersburg Institute of Bioregulation and Gerontology and collaborating laboratories, principally in Bulletin of Experimental Biology and Medicine (BEBM). No Western Phase 1 or later trials have been published.
Bronchogen is a synthetic tetrapeptide of the Khavinson sequence-specific bioregulator class. The Khavinson model proposes that short peptides isolated from or synthesized to mimic peptide fractions of specific tissues exert tissue-targeted effects on cell proliferation, differentiation, and gene expression — for bronchogen, on bronchial epithelium. Reported molecular activity includes binding to DNA (Monaselidze 2011 measured a stabilizing effect on DNA melting thermodynamics) and modulation of gene expression in cell culture. The tissue-targeting hypothesis itself — that a four-residue peptide selectively addresses one cell type by sequence — has not been mechanistically established by independent groups.
Tier 4. The principal indexed primary record for bronchogen is biophysical (DNA-binding measurements) rather than clinical. There are no Phase 1 or later human trials of bronchogen. Russian-language gerontology literature describes bronchogen-related preparations within broader peptide-bioregulator series.
No formal human safety database in indexed Western literature. Russian-origin clinical use within the peptide-bioregulator series reports good tolerability without a structured pharmacovigilance dataset of the kind expected for FDA review.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication. The Khavinson tetrapeptide model — sequence-specific tissue-targeting bioregulators — has not been validated by independent labs. Vendor-sold material in the US research-chemical channel is sold against claims (bronchial regeneration, anti-aging of pulmonary tissue) that exceed the published evidence base. Buyers cannot cross-check vendor product identity or purity against any pharmaceutical reference standard.